An observational study in Prostate Cancer Metastatic, sponsored by Erasmus Medical Center. Recruiting at 1 site in Netherlands. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by Erasmus Medical Center · Observational
This prospective study aims to collect data and blood biomarkers from patients undergoing Lu-PSMA therapy at the Erasmus MC. In doing so, it will provide real-world efficacy and safety data on the drug, gather dosimetry data and explore putative biomarkers to identify patients who most benefit from Lu-PSMA treatment.
6,370 studies on the registry are indexed under Prostatic Neoplasms; 1,400 are open to participants now.
This study's planned enrollment of 150 is below the median of 200 across 1,181 observational studies indexed under Prostatic Neoplasms.
Browse Prostatic Neoplasms studies →Erasmus Medical Center is the lead sponsor of 466 studies on the registry; 179 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients diagnosed with metastatic castration resistant prostate cancer set to receive treatment with Lutetium-177 Prostate Specific Membrane Antigen (Lu-PSMA) as a part of regular clinical care.
Exclusion Criteria:
None applicable
During routine blood sample collection, additional blood will be drawn for analysis of ctDNA and to collect Circulating Tumor Cells.
Overall survival
Overall survival will be defined as the time from inclusion to death from any cause.
Time frame: 44 months
Progression free survival
Progression free survival will be defined as clinical, radiological or PSA progression according to Prostate Cancer Working Group 3 (PCWG3) or death, whichever occurs first.
Time frame: 44 months
Heterogeneity of PSMA-positivity
Exploring heterogeneity of PSMA-positivity in circulating tumor cells (CTC) prior to treatment with Lutetium-PSMA.
Time frame: 44 months
Effect of CTC PSMA expression on response to treatment.
Exploring whether there is an association between the fraction of PSMA positive CTCs and response to Lutetium-PSMA treatment.
Time frame: 44 months
Effect of biomarkers in blood on response to treatment.
Exploring the association between biomarkers in blood and response to treatment
Time frame: 44 months
PSMA-PET scan data and response to treatment.
Exploring associations between PSMA-PET and therapy scans and response to treatment.
Time frame: 44 months
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Erasmus Medical Center